ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes
Year: 2022
Type: article
Abstract: PB has acted as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Sanofi, Novo Nordisk and Horizon Pharma. PB serves on the advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and XORTX. RPW has research support from Dexcom, Eli Lilly & Co and Tandem Diabetes Care. RPW has served on an advisory board for Dompe.
Source: Pediatric Diabetes
DOI: 10.1111/pedi.13444
Institutions: University of Colorado Anschutz, University of Colorado Denver, Children's Hospital Research Institute of Manitoba, The University of Sydney, Children's Hospital at Westmead, Jena University Hospital, University of Michigan, Michigan Medicine, National University of Singapore, Singapore National Eye Center, Singapore Eye Research Institute, Duke-NUS Medical School, Bangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4311973522